On January 21, 2026, Terilyn J. Monroe, Guardant Health, Inc.'s Chief People Officer, executed the sale of 8,571 shares of the company's common stock, as detailed in a recent Form 4 filing submitted to the U.S. Securities and Exchange Commission. The disposition generated proceeds of approximately $977,901, with executed share prices fluctuating between $112.34 and $115.70 across multiple transactions.
A breakdown of the trades reveals that Monroe sold 1,703 shares at an average price of $112.34 per share, 3,619 shares averaging $113.48, and an additional 3,249 shares at an average price of $115.70. Subsequent to these sales, Monroe retains ownership of 20,990 Guardant Health shares.
Concurrently, Guardant Health has secured Food and Drug Administration approval for its Guardant360 CDx assay, designating it as a companion diagnostic to detect BRAF V600E-mutant metastatic colorectal cancer patients. This milestone was underpinned by robust clinical data derived from Pfizer's Phase 3 BREAKWATER study, which demonstrated meaningful clinical benefits using a regimen of encorafenib and cetuximab coupled with chemotherapy.
Reflecting these favorable developments, investment banking firms Stifel and Jefferies have upgraded their price targets on Guardant Health's shares to $120 and $130 respectively, while affirming Buy ratings. These updates incorporate expectations of sustained growth and significant upcoming catalysts. Furthermore, BTIG has identified Guardant Health as one of its leading recommendations for 2026, citing the company's potential driven by products such as Shield CRC and Shield MCED.
In addition to U.S.-based advancements, Guardant Health's technological footprint has expanded internationally. In Italy, the Fondazione Policlinico Universitario Agostino Gemelli IRCCS has inaugurated an on-site liquid biopsy testing facility utilizing Guardant Health's platform, enhancing local cancer diagnostic capabilities by enabling comprehensive genomic profiling without the logistical delays of sending samples abroad.